Global Heart Failure Testing Market

Heart Failure Testing Comprehensive Study by Type (Blood tests, Chest X-ray, Electrocardiogram (ECG), Echocardiogram, Others (Stress test, CT, MRI, Coronary Angiogram)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others), Method (Electrocardiogram Testing, Blood Testing, Others), End User (Hospitals, Diagnostic Laboratories, Cardiac Care Centers, Others) Players and Region - Global Market Outlook to 2030

Heart Failure Testing Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Heart Failure Testing
Over the past few decades, instances of heart failures and heart-related diseases have prevailed across the globe, thereby upsurging the need for heart failure control across the globe. This has ultimately upsurged the demand for heart failure testing through Blood tests, Chest X-ray, Electrocardiogram (ECG), Echocardiogram, Stress test, CT, MRI, Coronary Angiogram, and many others. The use of heart failure testing tools has a significant impact on limiting the higher occurrence of deaths due to heart failures. Moreover, increasing government initiatives and reimbursements on intensive R&Ds has further escalated the growth of the heart failure testing industry.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Heart Failure Testing market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Heart Failure Testing Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantageThe Players having a strong hold in the market are Abbott Laboratories, Response Biomedical, Roche Holding, Trinity Biotech, and Quidel. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Heart Failure Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Response Biomedical Corporation (Canada), Roche Holding AG (Switzerland), Trinity Biotech (Ireland), Quidel Corporation (United States), Siemens AG (Germany), BioMérieux (France), General Electric Company (GE) (United States) and Koninklijke Philips N.V. (Netherlands) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Becton, Dickinson, and Company (United States), Bio-Rad Laboratories, Inc. (United States), PerkinElmer, Inc. (United States), Tosoh Corporation (Japan), Danaher Corporation (United States) and Thermo Fisher Scientific (United States).

Segmentation Overview
AMA Research has segmented the market of Global Heart Failure Testing market by Type (Blood tests, Chest X-ray, Electrocardiogram (ECG), Echocardiogram and Others (Stress test, CT, MRI, Coronary Angiogram)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis and Others) and Region.



On the basis of geography, the market of Heart Failure Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Method, the sub-segment i.e. Electrocardiogram Testing will boost the Heart Failure Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Heart Failure Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Affordability of Cardio Vascular Treatments and Increasing Disposable Incomes and Introduction to Highly Efficient Cardiac Biomarkers

Market Growth Drivers:
Growth of Research and Developments in Tackling Critical Heart Diseases and Rising Prevalence of Cardio-Vascular Diseases across the Globe

Challenges:
Operational Complexities and the Dearth of Skilled Researchers

Restraints:
Technological Hindrance with Respect to Collection and Storage of Samples and Stringent Government Regulations on Approval and Use of Medical Devices

Opportunities:
Increasing R&D Infrastructure in Healthcare across the Developing Nations and Rising Consumer Eagerness towards Healthcare Expenditure

Market Leaders and their expansionary development strategies
In January 2023, AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
In February 2023, Cardio Diagnostics Holdings announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.


Key Target Audience
New Entrants/Investors, Healthcare Industry Associations, Venture Capitalists and Private Equity Firms, Heart Testing Devices Manufacturers, Suppliers and Distributors, Raw Material Suppliers, End-Use Industries, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Blood tests
  • Chest X-ray
  • Electrocardiogram (ECG)
  • Echocardiogram
  • Others (Stress test, CT, MRI, Coronary Angiogram)
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
By Method
  • Electrocardiogram Testing
  • Blood Testing
  • Others

By End User
  • Hospitals
  • Diagnostic Laboratories
  • Cardiac Care Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth of Research and Developments in Tackling Critical Heart Diseases
      • 3.2.2. Rising Prevalence of Cardio-Vascular Diseases across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Operational Complexities and the Dearth of Skilled Researchers
    • 3.4. Market Trends
      • 3.4.1. Growing Affordability of Cardio Vascular Treatments and Increasing Disposable Incomes
      • 3.4.2. Introduction to Highly Efficient Cardiac Biomarkers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Heart Failure Testing, by Type, Application, Method, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Heart Failure Testing (Value)
      • 5.2.1. Global Heart Failure Testing by: Type (Value)
        • 5.2.1.1. Blood tests
        • 5.2.1.2. Chest X-ray
        • 5.2.1.3. Electrocardiogram (ECG)
        • 5.2.1.4. Echocardiogram
        • 5.2.1.5. Others (Stress test, CT, MRI, Coronary Angiogram)
      • 5.2.2. Global Heart Failure Testing by: Application (Value)
        • 5.2.2.1. Myocardial Infarction
        • 5.2.2.2. Congestive Heart Failure
        • 5.2.2.3. Acute Coronary Syndrome
        • 5.2.2.4. Atherosclerosis
        • 5.2.2.5. Others
      • 5.2.3. Global Heart Failure Testing by: Method (Value)
        • 5.2.3.1. Electrocardiogram Testing
        • 5.2.3.2. Blood Testing
        • 5.2.3.3. Others
      • 5.2.4. Global Heart Failure Testing by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Diagnostic Laboratories
        • 5.2.4.3. Cardiac Care Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Heart Failure Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Heart Failure Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Response Biomedical Corporation (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Trinity Biotech (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Quidel Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Siemens AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioMérieux (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. General Electric Company (GE) (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Koninklijke Philips N.V. (Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Heart Failure Testing Sale, by Type, Application, Method, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Heart Failure Testing (Value)
      • 7.2.1. Global Heart Failure Testing by: Type (Value)
        • 7.2.1.1. Blood tests
        • 7.2.1.2. Chest X-ray
        • 7.2.1.3. Electrocardiogram (ECG)
        • 7.2.1.4. Echocardiogram
        • 7.2.1.5. Others (Stress test, CT, MRI, Coronary Angiogram)
      • 7.2.2. Global Heart Failure Testing by: Application (Value)
        • 7.2.2.1. Myocardial Infarction
        • 7.2.2.2. Congestive Heart Failure
        • 7.2.2.3. Acute Coronary Syndrome
        • 7.2.2.4. Atherosclerosis
        • 7.2.2.5. Others
      • 7.2.3. Global Heart Failure Testing by: Method (Value)
        • 7.2.3.1. Electrocardiogram Testing
        • 7.2.3.2. Blood Testing
        • 7.2.3.3. Others
      • 7.2.4. Global Heart Failure Testing by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Diagnostic Laboratories
        • 7.2.4.3. Cardiac Care Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Heart Failure Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Heart Failure Testing: by Type(USD Million)
  • Table 2. Heart Failure Testing Blood tests , by Region USD Million (2018-2023)
  • Table 3. Heart Failure Testing Chest X-ray , by Region USD Million (2018-2023)
  • Table 4. Heart Failure Testing Electrocardiogram (ECG) , by Region USD Million (2018-2023)
  • Table 5. Heart Failure Testing Echocardiogram , by Region USD Million (2018-2023)
  • Table 6. Heart Failure Testing Others (Stress test, CT, MRI, Coronary Angiogram) , by Region USD Million (2018-2023)
  • Table 7. Heart Failure Testing: by Application(USD Million)
  • Table 8. Heart Failure Testing Myocardial Infarction , by Region USD Million (2018-2023)
  • Table 9. Heart Failure Testing Congestive Heart Failure , by Region USD Million (2018-2023)
  • Table 10. Heart Failure Testing Acute Coronary Syndrome , by Region USD Million (2018-2023)
  • Table 11. Heart Failure Testing Atherosclerosis , by Region USD Million (2018-2023)
  • Table 12. Heart Failure Testing Others , by Region USD Million (2018-2023)
  • Table 13. Heart Failure Testing: by Method(USD Million)
  • Table 14. Heart Failure Testing Electrocardiogram Testing , by Region USD Million (2018-2023)
  • Table 15. Heart Failure Testing Blood Testing , by Region USD Million (2018-2023)
  • Table 16. Heart Failure Testing Others , by Region USD Million (2018-2023)
  • Table 17. Heart Failure Testing: by End User(USD Million)
  • Table 18. Heart Failure Testing Hospitals , by Region USD Million (2018-2023)
  • Table 19. Heart Failure Testing Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 20. Heart Failure Testing Cardiac Care Centers , by Region USD Million (2018-2023)
  • Table 21. Heart Failure Testing Others , by Region USD Million (2018-2023)
  • Table 22. South America Heart Failure Testing, by Country USD Million (2018-2023)
  • Table 23. South America Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 24. South America Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 25. South America Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 26. South America Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 27. Brazil Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 28. Brazil Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 29. Brazil Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 30. Brazil Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 31. Argentina Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 32. Argentina Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 33. Argentina Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 34. Argentina Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 35. Rest of South America Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 38. Rest of South America Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 39. Asia Pacific Heart Failure Testing, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 41. Asia Pacific Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 42. Asia Pacific Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 43. Asia Pacific Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 44. China Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 45. China Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 46. China Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 47. China Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 48. Japan Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 49. Japan Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 50. Japan Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 51. Japan Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 52. India Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 53. India Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 54. India Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 55. India Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 56. South Korea Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 57. South Korea Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 58. South Korea Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 59. South Korea Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 60. Taiwan Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 61. Taiwan Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 62. Taiwan Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 63. Taiwan Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 64. Australia Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 65. Australia Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 66. Australia Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 67. Australia Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 72. Europe Heart Failure Testing, by Country USD Million (2018-2023)
  • Table 73. Europe Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 74. Europe Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 75. Europe Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 76. Europe Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 77. Germany Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 78. Germany Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 79. Germany Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 80. Germany Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 81. France Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 82. France Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 83. France Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 84. France Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 85. Italy Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 86. Italy Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 87. Italy Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 88. Italy Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 89. United Kingdom Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 90. United Kingdom Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 91. United Kingdom Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 92. United Kingdom Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 93. Netherlands Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 94. Netherlands Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 95. Netherlands Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 96. Netherlands Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 97. Rest of Europe Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 98. Rest of Europe Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 99. Rest of Europe Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 100. Rest of Europe Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 101. MEA Heart Failure Testing, by Country USD Million (2018-2023)
  • Table 102. MEA Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 103. MEA Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 104. MEA Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 105. MEA Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 106. Middle East Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 107. Middle East Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 108. Middle East Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 109. Middle East Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 110. Africa Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 111. Africa Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 112. Africa Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 113. Africa Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 114. North America Heart Failure Testing, by Country USD Million (2018-2023)
  • Table 115. North America Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 116. North America Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 117. North America Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 118. North America Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 119. United States Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 120. United States Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 121. United States Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 122. United States Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 123. Canada Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 124. Canada Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 125. Canada Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 126. Canada Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 127. Mexico Heart Failure Testing, by Type USD Million (2018-2023)
  • Table 128. Mexico Heart Failure Testing, by Application USD Million (2018-2023)
  • Table 129. Mexico Heart Failure Testing, by Method USD Million (2018-2023)
  • Table 130. Mexico Heart Failure Testing, by End User USD Million (2018-2023)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Heart Failure Testing: by Type(USD Million)
  • Table 141. Heart Failure Testing Blood tests , by Region USD Million (2025-2030)
  • Table 142. Heart Failure Testing Chest X-ray , by Region USD Million (2025-2030)
  • Table 143. Heart Failure Testing Electrocardiogram (ECG) , by Region USD Million (2025-2030)
  • Table 144. Heart Failure Testing Echocardiogram , by Region USD Million (2025-2030)
  • Table 145. Heart Failure Testing Others (Stress test, CT, MRI, Coronary Angiogram) , by Region USD Million (2025-2030)
  • Table 146. Heart Failure Testing: by Application(USD Million)
  • Table 147. Heart Failure Testing Myocardial Infarction , by Region USD Million (2025-2030)
  • Table 148. Heart Failure Testing Congestive Heart Failure , by Region USD Million (2025-2030)
  • Table 149. Heart Failure Testing Acute Coronary Syndrome , by Region USD Million (2025-2030)
  • Table 150. Heart Failure Testing Atherosclerosis , by Region USD Million (2025-2030)
  • Table 151. Heart Failure Testing Others , by Region USD Million (2025-2030)
  • Table 152. Heart Failure Testing: by Method(USD Million)
  • Table 153. Heart Failure Testing Electrocardiogram Testing , by Region USD Million (2025-2030)
  • Table 154. Heart Failure Testing Blood Testing , by Region USD Million (2025-2030)
  • Table 155. Heart Failure Testing Others , by Region USD Million (2025-2030)
  • Table 156. Heart Failure Testing: by End User(USD Million)
  • Table 157. Heart Failure Testing Hospitals , by Region USD Million (2025-2030)
  • Table 158. Heart Failure Testing Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 159. Heart Failure Testing Cardiac Care Centers , by Region USD Million (2025-2030)
  • Table 160. Heart Failure Testing Others , by Region USD Million (2025-2030)
  • Table 161. South America Heart Failure Testing, by Country USD Million (2025-2030)
  • Table 162. South America Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 163. South America Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 164. South America Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 165. South America Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 166. Brazil Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 167. Brazil Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 168. Brazil Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 169. Brazil Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 170. Argentina Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 171. Argentina Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 172. Argentina Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 173. Argentina Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 174. Rest of South America Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 175. Rest of South America Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 176. Rest of South America Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 177. Rest of South America Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 178. Asia Pacific Heart Failure Testing, by Country USD Million (2025-2030)
  • Table 179. Asia Pacific Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 180. Asia Pacific Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 181. Asia Pacific Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 182. Asia Pacific Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 183. China Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 184. China Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 185. China Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 186. China Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 187. Japan Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 188. Japan Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 189. Japan Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 190. Japan Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 191. India Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 192. India Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 193. India Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 194. India Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 195. South Korea Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 196. South Korea Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 197. South Korea Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 198. South Korea Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 199. Taiwan Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 200. Taiwan Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 201. Taiwan Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 202. Taiwan Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 203. Australia Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 204. Australia Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 205. Australia Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 206. Australia Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 211. Europe Heart Failure Testing, by Country USD Million (2025-2030)
  • Table 212. Europe Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 213. Europe Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 214. Europe Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 215. Europe Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 216. Germany Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 217. Germany Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 218. Germany Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 219. Germany Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 220. France Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 221. France Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 222. France Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 223. France Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 224. Italy Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 225. Italy Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 226. Italy Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 227. Italy Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 228. United Kingdom Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 229. United Kingdom Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 230. United Kingdom Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 231. United Kingdom Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 232. Netherlands Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 233. Netherlands Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 234. Netherlands Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 235. Netherlands Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 236. Rest of Europe Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 237. Rest of Europe Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 238. Rest of Europe Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 239. Rest of Europe Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 240. MEA Heart Failure Testing, by Country USD Million (2025-2030)
  • Table 241. MEA Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 242. MEA Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 243. MEA Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 244. MEA Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 245. Middle East Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 246. Middle East Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 247. Middle East Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 248. Middle East Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 249. Africa Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 250. Africa Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 251. Africa Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 252. Africa Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 253. North America Heart Failure Testing, by Country USD Million (2025-2030)
  • Table 254. North America Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 255. North America Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 256. North America Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 257. North America Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 258. United States Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 259. United States Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 260. United States Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 261. United States Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 262. Canada Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 263. Canada Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 264. Canada Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 265. Canada Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 266. Mexico Heart Failure Testing, by Type USD Million (2025-2030)
  • Table 267. Mexico Heart Failure Testing, by Application USD Million (2025-2030)
  • Table 268. Mexico Heart Failure Testing, by Method USD Million (2025-2030)
  • Table 269. Mexico Heart Failure Testing, by End User USD Million (2025-2030)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Heart Failure Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Heart Failure Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Heart Failure Testing: by Method USD Million (2018-2023)
  • Figure 7. Global Heart Failure Testing: by End User USD Million (2018-2023)
  • Figure 8. South America Heart Failure Testing Share (%), by Country
  • Figure 9. Asia Pacific Heart Failure Testing Share (%), by Country
  • Figure 10. Europe Heart Failure Testing Share (%), by Country
  • Figure 11. MEA Heart Failure Testing Share (%), by Country
  • Figure 12. North America Heart Failure Testing Share (%), by Country
  • Figure 13. Global Heart Failure Testing share by Players 2023 (%)
  • Figure 14. Global Heart Failure Testing share by Players (Top 3) 2023(%)
  • Figure 15. Global Heart Failure Testing share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. Response Biomedical Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 20. Response Biomedical Corporation (Canada) Revenue: by Geography 2023
  • Figure 21. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Trinity Biotech (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Trinity Biotech (Ireland) Revenue: by Geography 2023
  • Figure 25. Quidel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Quidel Corporation (United States) Revenue: by Geography 2023
  • Figure 27. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 29. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 30. BioMérieux (France) Revenue: by Geography 2023
  • Figure 31. General Electric Company (GE) (United States) Revenue, Net Income and Gross profit
  • Figure 32. General Electric Company (GE) (United States) Revenue: by Geography 2023
  • Figure 33. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 34. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 35. Global Heart Failure Testing: by Type USD Million (2025-2030)
  • Figure 36. Global Heart Failure Testing: by Application USD Million (2025-2030)
  • Figure 37. Global Heart Failure Testing: by Method USD Million (2025-2030)
  • Figure 38. Global Heart Failure Testing: by End User USD Million (2025-2030)
  • Figure 39. South America Heart Failure Testing Share (%), by Country
  • Figure 40. Asia Pacific Heart Failure Testing Share (%), by Country
  • Figure 41. Europe Heart Failure Testing Share (%), by Country
  • Figure 42. MEA Heart Failure Testing Share (%), by Country
  • Figure 43. North America Heart Failure Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Response Biomedical Corporation (Canada)
  • Roche Holding AG (Switzerland)
  • Trinity Biotech (Ireland)
  • Quidel Corporation (United States)
  • Siemens AG (Germany)
  • BioMérieux (France)
  • General Electric Company (GE) (United States)
  • Koninklijke Philips N.V. (Netherlands)
Additional players considered in the study are as follows:
Becton, Dickinson, and Company (United States) , Bio-Rad Laboratories, Inc. (United States) , PerkinElmer, Inc. (United States) , Tosoh Corporation (Japan) , Danaher Corporation (United States) , Thermo Fisher Scientific (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 239 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Heart Failure Testing Market Quantitative research analysis
Global Heart Failure Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Response Biomedical Corporation (Canada), Roche Holding AG (Switzerland), Trinity Biotech (Ireland), Quidel Corporation (United States), Siemens AG (Germany), BioMérieux (France), General Electric Company (GE) (United States) and Koninklijke Philips N.V. (Netherlands) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Affordability of Cardio Vascular Treatments and Increasing Disposable Incomes " is seen as one of major influencing trends for Heart Failure Testing Market during projected period 2023-2030.
The Heart Failure Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Heart Failure Testing Market Report?

Have a Query? Click Here

Other Related Reports

Clinical Electrophoresis Comprehensive Study by Type (Routine (Zone) Electrophoresis, High Resolution (HRE) Electrophoresis, Polyacrylamide (PAGE) Electrophoresis, Capillary (CE) Electrophoresis, Iso...
$ 3750
Novel Cell Sorting and Separation Comprehensive Study by Type (Cancer Cell, Immune Cells, Microbial Cell, Red Blood Cell/Platelet, Stem Cell, Others), Application (Academic Institutes, Clinical Testi...
$ 3750
Network Connected Medical Devices Comprehensive Study by Type (Wearable, Implantable Device), Application (Hospital, Clinic, Other), Connectivity (BLE, Wi-Fi, NFC, Cellular), Devices (Patient Monitor...
$ 3650
Intramuscular Drug Delivery Comprehensive Study by Type (Oral (Swallowed Into The Stomach), Intravenous (Injected Into The Vein), Subcutaneous (Injected Into The Fatty Tissue Just Under The Layer Of ...
$ 3750
Point of Care Molecular Diagnostics Comprehensive Study by Type (Rt-Pcr, Inaat, Industry Segmentation, Physician Offices, Hospital Emergency Departments & Intensive Care Units, Research Institutes, C...
$ 3750
Ambulatory Healthcare Service Comprehensive Study by Type (Blood Tests, Biopsy, Chemotherapy, Colonoscopy, CT Scan, Mammograms, Minor Surgical Procedures), Application (Outpatient Department, Primary...
$ 3750